Put companies on watchlist
Cannovum AG
ISIN: DE000A2LQU21
WKN: A2LQU2
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cannovum AG · ISIN: DE000A2LQU21 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1611415
19 April 2023 09:44AM

Cannovum AG develops cultivation kits for Cannabis Social Clubs


EQS-News: Cannovum AG / Key word(s): Product Launch/Strategic Company Decision
Cannovum AG develops cultivation kits for Cannabis Social Clubs

19.04.2023 / 09:44 CET/CEST
The issuer is solely responsible for the content of this announcement.


Cannovum AG (Stock market Frankfurt, Xetra, Duesseldorf, Munich, Hamburg, Berlin, Tradegate, gettex: ISIN DE000A2LQU21) is partnering up with the Anbau-Allianz to develop cultivation kits with the necessary products for the new Cannabis Social Clubs, other services will complement this offer.

 

With these products, Cannovum AG will actively support the upcoming legalization of recreational cannabis in Germany. The German government's decision to legalize the distribution of legal cannabis is opening huge opportunities. Cannovum AG had already prepared for this development in advance with its partners from the Anbau Allianz.

 

Cannovum AG is developing a wide range of cultivation kits that contain the necessary components to grow high-quality cannabis. The kits contain seeds, nutrients, grow lights and other products needed to successfully grow cannabis plants. These cultivation kits are developed specifically for the Cannabis Social Clubs that are part of the legalization movement in Germany. The exact contents are based on the legal requirements that will be published by the German government in the coming weeks.

 

"Cannovum AG is part of the legalization of cannabis in Germany. We will actively support the emerging Cannabis Social Clubs," says Pia Marten, CEO of Cannovum AG. "Our goal is to make high-quality cannabis accessible to people and to promote the legal cultivation of cannabis. For us, consumer health and youth protection is vital."

 

Elimar Moormann, partner of the Anbau-Allianz commented: "Our many years of experience in cultivation allow us to assemble the optimal components for the emerging Cannabis Social Clubs. We are glad that we can cultivate cannabis sustainably and green in our production facilities through our own existing regenerative energies."  As a partner of Cannovum AG, the Anbau-Allianz with co-founder Tim Spieker is the innovation driver for all topics related to the cultivation of recreational cannabis in Germany.

Klaus Madzia, CMO of Cannovum AG: "The cultivation kits will also enable newcomers to grow high-quality cannabis plants. Additionally, there will be other digital tools, such as online courses, support for club approvals, as well as online programs for community management." More information is available at www.anbau-allianz.de

 

Cannovum AG is traded on the stock market in Frankfurt, Xetra, Düsseldorf, Munich, Hamburg, Berlin, Tradegate and gettex under ISIN DE000A2LQU21.

 

 

Kontakt:

Klaus Madzia

IR & PR

Cannovum AG

Telefon: +49 30 3982 163 62

E-Mail: klaus.madzia@cannovum.com

 

Cannovum AG is the first German fully licensed cannabis company listed on the stock exchange. The shares are traded on the Frankfurt, Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Cannovum AG is well prepared for the legalization of cannabis: for sales through pharmacies as well as through licensed specialty stores and online shipping.

 

Through its subsidiary Cannovum Health eG, the company is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. Already today, Cannovum AG is a market leader in the medical cannabis sector.

 

Currently, the company is active in the importation of high-quality cannabinoid precursors, medical-scientific education, and widespread distribution for a simplified and equitable access to cannabis-based therapies.

 



19.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: ir@cannovum.com
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich
EQS News ID: 1611415

 
End of News EQS News Service

1611415  19.04.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1611415&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.